SG10201701780RA - Nucleophilic catalysts for oxime linkage - Google Patents

Nucleophilic catalysts for oxime linkage

Info

Publication number
SG10201701780RA
SG10201701780RA SG10201701780RA SG10201701780RA SG10201701780RA SG 10201701780R A SG10201701780R A SG 10201701780RA SG 10201701780R A SG10201701780R A SG 10201701780RA SG 10201701780R A SG10201701780R A SG 10201701780RA SG 10201701780R A SG10201701780R A SG 10201701780RA
Authority
SG
Singapore
Prior art keywords
oxime linkage
nucleophilic catalysts
nucleophilic
catalysts
oxime
Prior art date
Application number
SG10201701780RA
Other languages
English (en)
Inventor
Juergen Siekmann
Stefan Haider
Hanspeter Rottensteiner
Peter Turecek
Original Assignee
Baxalta Inc
Baxalta GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/488,043 external-priority patent/US8809501B2/en
Application filed by Baxalta Inc, Baxalta GmbH filed Critical Baxalta Inc
Publication of SG10201701780RA publication Critical patent/SG10201701780RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Water Supply & Treatment (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG10201701780RA 2012-05-16 2013-05-16 Nucleophilic catalysts for oxime linkage SG10201701780RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261647814P 2012-05-16 2012-05-16
US13/488,043 US8809501B2 (en) 2009-07-27 2012-06-04 Nucleophilic catalysts for oxime linkage

Publications (1)

Publication Number Publication Date
SG10201701780RA true SG10201701780RA (en) 2017-04-27

Family

ID=48579473

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201911328QA SG10201911328QA (en) 2012-05-16 2013-05-16 Nucleophilic catalysts for oxime linkage
SG10201701780RA SG10201701780RA (en) 2012-05-16 2013-05-16 Nucleophilic catalysts for oxime linkage
SG11201407597XA SG11201407597XA (en) 2012-05-16 2013-05-16 Nucleophilic catalysts for oxime linkage

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201911328QA SG10201911328QA (en) 2012-05-16 2013-05-16 Nucleophilic catalysts for oxime linkage

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201407597XA SG11201407597XA (en) 2012-05-16 2013-05-16 Nucleophilic catalysts for oxime linkage

Country Status (13)

Country Link
EP (3) EP4019049A1 (no)
JP (5) JP6195611B2 (no)
KR (4) KR102110622B1 (no)
CN (2) CN104487095B (no)
AU (1) AU2013204754C1 (no)
BR (1) BR112014028636B1 (no)
CA (1) CA2873756C (no)
EA (2) EA035506B1 (no)
HK (1) HK1209024A1 (no)
MX (1) MX360594B (no)
NZ (4) NZ738846A (no)
SG (3) SG10201911328QA (no)
WO (2) WO2013173543A1 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013204754C1 (en) * 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
KR20190084287A (ko) * 2016-11-14 2019-07-16 노파르티스 아게 연골 손상 및 관절염 치료 방법 및 조성물
JP7002036B2 (ja) * 2016-11-17 2022-01-20 パナソニックＩｐマネジメント株式会社 膜電極接合体および固体酸化物形燃料電池
US11786586B2 (en) 2016-12-23 2023-10-17 Aoa Dx Carbohydrate structures and uses thereof
CN108503901B (zh) * 2018-04-17 2020-07-07 哈尔滨工业大学 一种抗菌普鲁兰多糖/壳聚糖复合食品包装膜的制备方法
EP3914711A2 (en) 2019-01-23 2021-12-01 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors
US11845989B2 (en) 2019-01-23 2023-12-19 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
CA3210480A1 (en) 2021-02-26 2022-09-01 Regeneron Pharmaceuticals, Inc. Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (angptl7) inhibitors

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54113492A (en) 1978-02-24 1979-09-05 Sanyo Chem Ind Ltd Preparation of glucoprotein derivative
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US5198349A (en) 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
KR100303872B1 (ko) 1992-10-02 2001-11-22 크리스터 발스트룀, 프레드릭 베르그, 하랄트 알름 응고인자ⅷ제형을포함하는조성물,이것의제조방법및안정화제로서의계면활성제의사용방법
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
WO1994028024A1 (en) * 1993-06-01 1994-12-08 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
WO1996040662A2 (en) 1995-06-07 1996-12-19 Cellpro, Incorporated Aminooxy-containing linker compounds and their application in conjugates
US6531298B2 (en) 1997-07-21 2003-03-11 The University Of North Carolina At Chapel Hill Factor IX antihemophilic factor with increased clotting activity
US7074878B1 (en) 1999-12-10 2006-07-11 Harris J Milton Hydrolytically degradable polymers and hydrogels made therefrom
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
ES2256234T3 (es) 2000-05-16 2006-07-16 Lipoxen Technologies Limited Derivatizacion de proteinas en solucion acuosa.
WO2004099231A2 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
JP4758608B2 (ja) 2001-11-07 2011-08-31 ネクター セラピューティックス 分枝ポリマーおよびそれらの結合体
KR101045422B1 (ko) 2002-09-11 2011-06-30 프레제니우스 카비 도이치란트 게엠베하 하이드록시알킬 전분 유도체의 제조 방법
EP1681303B1 (en) 2002-09-11 2013-09-04 Fresenius Kabi Deutschland GmbH HASylated polypeptides, especially HASylated erythropoietin
JP4698579B2 (ja) 2003-04-08 2011-06-08 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 可逆的ｐｅｇ化薬物
US20080206182A1 (en) * 2003-08-08 2008-08-28 Fresenius Kabi Deutschland Gmbh Conjugates of a Polymer and a Protein Linked by an Oxime Group
KR101113726B1 (ko) 2003-08-12 2012-02-27 리폭센 테크놀로지즈 리미티드 단백질 유도 및 컨쥬게이션용 시알산 유도체
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
EP1694274B1 (en) 2003-12-03 2013-04-24 BioGeneriX AG Glycopegylated granulocyte colony stimulating factor
ES2593318T3 (es) 2004-08-12 2016-12-07 Lipoxen Technologies Limited Derivados de ácido siálico
US8268967B2 (en) 2004-09-10 2012-09-18 Novo Nordisk A/S Glycopegylated interferon α
DK1835938T3 (da) 2004-12-27 2013-11-04 Baxter Int Polymer-von Willebrand-faktor-konjugater
EP1896082B1 (en) 2005-06-16 2012-12-26 Nektar Therapeutics Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
ES2531934T3 (es) 2006-09-01 2015-03-20 Novo Nordisk Health Care Ag Glicoproteínas modificadas
EP2101821B1 (en) * 2006-12-15 2014-08-13 Baxter International Inc. Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life
GB0908393D0 (en) * 2009-05-15 2009-06-24 Almac Sciences Scotland Ltd Labelling method
NZ597600A (en) * 2009-07-27 2014-05-30 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
EP2459224B1 (en) * 2009-07-27 2016-06-01 Baxalta GmbH Blood coagulation protein conjugates
KR102269494B1 (ko) * 2010-07-30 2021-06-25 박스알타 인코퍼레이티드 옥심 결합용 친핵성 촉매
KR101560541B1 (ko) * 2012-04-13 2015-10-19 아우토리브 디벨롭먼트 아베 에어백 모듈과 스티어링 휠의 조립체
AU2013204754C1 (en) * 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage

Also Published As

Publication number Publication date
EP4019049A1 (en) 2022-06-29
MX360594B (es) 2018-11-09
JP6195611B2 (ja) 2017-09-13
JP2020111599A (ja) 2020-07-27
KR102237306B1 (ko) 2021-04-08
EA201790935A1 (ru) 2017-12-29
NZ724828A (en) 2018-02-23
KR20200053636A (ko) 2020-05-18
KR20210041629A (ko) 2021-04-15
KR102110622B1 (ko) 2020-05-14
KR102287040B1 (ko) 2021-08-09
BR112014028636B1 (pt) 2022-09-20
JP2022034075A (ja) 2022-03-02
HK1209024A1 (en) 2016-03-24
JP2017145260A (ja) 2017-08-24
MX2014013919A (es) 2015-06-05
CA2873756C (en) 2022-08-16
JP2019089810A (ja) 2019-06-13
KR20150008192A (ko) 2015-01-21
AU2013204754B2 (en) 2015-11-05
CN109620963B (zh) 2022-10-28
EA035506B1 (ru) 2020-06-25
BR112014028636A2 (no) 2017-08-15
JP6560712B2 (ja) 2019-08-14
NZ738844A (en) 2018-12-21
EP2849794A1 (en) 2015-03-25
JP7304402B2 (ja) 2023-07-06
JP2015520163A (ja) 2015-07-16
SG10201911328QA (en) 2020-01-30
NZ701945A (en) 2016-10-28
JP7014844B2 (ja) 2022-02-01
EP2849795B1 (en) 2022-04-06
EP2849795A1 (en) 2015-03-25
CN104487095B (zh) 2018-12-07
AU2013204754C1 (en) 2018-10-11
CN109620963A (zh) 2019-04-16
CN104487095A (zh) 2015-04-01
EA028186B9 (ru) 2018-05-31
KR102326360B1 (ko) 2021-11-15
CA2873756A1 (en) 2013-11-21
EA028186B1 (ru) 2017-10-31
SG11201407597XA (en) 2014-12-30
EA201492115A1 (ru) 2015-05-29
WO2013173557A1 (en) 2013-11-21
WO2013173543A1 (en) 2013-11-21
NZ738846A (en) 2019-05-31
JP6711935B2 (ja) 2020-06-17
KR20210099187A (ko) 2021-08-11

Similar Documents

Publication Publication Date Title
GB201721108D0 (en) Catalyst blends
GB2502030C (en) Catalysts
ZA201307534B (en) Catalysts
EP2825850A4 (en) SEGMENT VALIDATION
GB201116713D0 (en) Catalyst
EP2764663A4 (en) WIRELESS DIAGNOSTIC SYSTEM
HK1208197A1 (en) Reduction catalysts
EP2786902A4 (en) DEVICE FOR ACTUATING A VEHICLE
HK1209024A1 (en) Nucleophilic catalysts for oxime linkage
SG10201913078SA (en) Nucleophilic catalysts for oxime linkage
EP2700447A4 (en) SILICONE OXIDE FILLED CATALYST
EP2859438A4 (en) OPERATING SYSTEM
ZA201404910B (en) Catalysts
AU2013204754A1 (en) Nucleophilic Catalysts for Oxime Linkage
ZA201409034B (en) Catalysts
AP3757A (en) Catalysts
HRP20190552T1 (hr) Mehanizam za sklopive krevete na kat
GB2508511B (en) Bimetallic catalyst
GB2504567B (en) Anti-Relatch Mechanism
GB201220691D0 (en) A catalyst
EP2753627A4 (en) CATALYSIS
HK1212895A1 (zh) 用於免疫調節的沙奎那韋-
GB2488127B (en) Operation system for umbrellas
GB201213825D0 (en) Damper-device for bouncing-device
GB201102101D0 (en) Catalysts